Skip to main content
. Author manuscript; available in PMC: 2017 Nov 21.
Published in final edited form as: ChemMedChem. 2016 Oct 18;11(22):2511–2521. doi: 10.1002/cmdc.201600421

Table 6.

Effects of mutation azi-9 on MIC SecA inhibitors resistance in E. coli

Assays E. coli strains PMBN SCA-107
A. Inhibitor sensitivity at 37°C, MIC (μg/mL). NR698 − 2.2
MC4100 − >590*
+ 2.6
DO318 (azi-9) + >37.8
Other prlD* + 0.7–3.0
B. Complementation at 42°C, MIC (μg/mL). MC4100 − >566*
+ 2.0
DO318 − >566*
+ >50
BA13/secA − >357*
+ 1.8
BA13/secA-azi-9 − >566
+ 11.0
A

MIC (μg/mL) of E. coli azide resistant strain DO318 (azi-9, EcSecA L515F) at 37°C. PMBN when used was at 25 μg/mL. *Other E. coli prlD mutants are all azide resistant or supersensitive strains, including az-R mutation in prlD5(A373V), prlD2(A488V), prlD22(Y134C), prlD43(H484Q), prlD4(T111N), azi-4 (L645Q), azi-630(A630V), azi-656(R656C), azi-7(N179Y), azi-6, SecA(Δ519–547) and az-SS mutation prlD20(A507V), and prlD43(H484O).

B

MIC (μg/mL) of complementation test of azi-9 mutation. Complementation of azi-9 mutation (EcSecA L515F) in vivo drug resistance, E. coli secAam, supFts mutant BA 13 containing plasmid ecsecA wild-type or ecsecA-azi-9 mutant were subjected to MIC test at 42C with or without 25 μg/mL PMBN.